What is GeneDx Holdings's return on equity?

GeneDx Holdings (WGS) reported return on equity of -30.4% in Q1 2026.

What is the long-term trend for GeneDx Holdings's return on equity?

Over 2 years (2022 to 2025), GeneDx Holdings's return on equity has grown at a -78.9% compound annual growth rate (CAGR), from -171.1% to -7.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

GeneDx Holdings WGS Return on equity

Return on equity at other companies

Natera, Inc.NTRA

-29%+4.1pp

Tempus AI, Inc.TEM

-81.6%—

Bio-Rad LaboratoriesBIO

2.5%+1.3pp

Quest DiagnosticsDGX

14.3%+0.9pp

RevvityRVTY

3.2%-0.5pp

Labcorp HoldingsLH

11.1%+2.1pp

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.72B-24.3%

Enterprise value$1.73B-22.8%

P/S3.9×-3.0×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Calculated from GeneDx Holdings’s reported figures.

net income/total stockholders equity=-30.4%

Based on trailing twelve months.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's return on equity?: GeneDx Holdings (WGS) reported return on equity of -30.4% in Q1 2026.
What is the long-term trend for GeneDx Holdings's return on equity?: Over 2 years (2022 to 2025), GeneDx Holdings's return on equity has grown at a -78.9% compound annual growth rate (CAGR), from -171.1% to -7.6%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.